Mylan NV (MYL)

17.27
0.04 0.23
NASDAQ : Health Technology
Prev Close 17.23
Open 17.33
Day Low/High 17.16 / 17.43
52 Wk Low/High 16.63 / 35.16
Volume 5.29M
Avg Volume 5.83M
Exchange NASDAQ
Shares Outstanding 516.13M
Market Cap 9.14B
EPS 0.70
P/E Ratio 196.67
Div & Yield N.A. (N.A)
There Is Nothing Generic About the Basing Action on Mylan

There Is Nothing Generic About the Basing Action on Mylan

Prices look set to test key resistance, and this time should see a breakout to the upside.

Mylan Benefits From Teva's Multiple Sclerosis Patent Dispute Woes

Mylan Benefits From Teva's Multiple Sclerosis Patent Dispute Woes

Mylan's shares rose after Teva's claims of patent infringement were rejected, despite the announcement that the FTC is investigating the drugmaker for antitrust violations.

Insulin Drug Offers Hope for MannKind

Insulin Drug Offers Hope for MannKind

The stock has taken a beating, but users of Afrezza are loyal to the drug.

Cigna Will No Longer Cover Mylan's EpiPen

Cigna Will No Longer Cover Mylan's EpiPen

Health insurance giant Cigna said it will no longer cover Mylan's EpiPen.

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.

Here's What to Look for at the J.P. Morgan Healthcare Conference

Here's What to Look for at the J.P. Morgan Healthcare Conference

The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.

Mylan downgraded at Citi

Cramer: Reviewing S&P's Hit-and-Miss Parade

Cramer: Reviewing S&P's Hit-and-Miss Parade

Even among the losers, buys are scarce.

Allergan Drug Price Hikes Are in Effect, Though Increases Are Modest

Allergan Drug Price Hikes Are in Effect, Though Increases Are Modest

Allergan raises the prices on nine drugs, but keeps the increases reasonable.

Make Sure Your Portfolio Is Protected From Volatility

Make Sure Your Portfolio Is Protected From Volatility

If you use TVIX and VXX put in an above-market limit order, or if you trade options buy calls on the VIX.

Watch Beaten-Down Drug Companies, Hospitals in 2017

Watch Beaten-Down Drug Companies, Hospitals in 2017

There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.

Jim Cramer on Mylan's New Generic EpiPen

Jim Cramer on Mylan's New Generic EpiPen

Mylan's EpiPen is going to start selling a generic version of its EpiPen allergy treatment with more than a 50% discount.

Mylan to Start Selling Generic Verisons of EpiPens at Half Price

Mylan to Start Selling Generic Verisons of EpiPens at Half Price

Mylan's much awaited generic version of its EpiPen treatment will be offered for sale next week, at a 50% discount.

Eli Lilly Teams With Express Scripts to Offer Discounted Insulin

Eli Lilly Teams With Express Scripts to Offer Discounted Insulin

Shares of Eli Lilly were higher Tuesday after announcing that starting January of 2017, customers will be able to purchase insulin at a discount of up to 40%.

Don't Blame Trump for Biotechs' Retreat

Don't Blame Trump for Biotechs' Retreat

The sector excelled right after the election, but lately has been sitting this rally out.

Closing Bell: Credit Suisse to Cut Jobs; Dow and S&P 500 Hit All-Time High

Closing Bell: Credit Suisse to Cut Jobs; Dow and S&P 500 Hit All-Time High

The Dow's winning streak continued with the index closing higher for the 18th time in 22 sessions and clinching a record settlement for the third day in a row.

Mylan: This Is Going to Take a While

Mylan: This Is Going to Take a While

The stock remains pointed down with few signs of encouragement for bulls.

Some 'January Effect' Stock Picks

Some 'January Effect' Stock Picks

Small-caps could also benefit from abating tax-loss selling.

Andrew Left: Dump Mallinckrodt

Andrew Left: Dump Mallinckrodt

Famed short-seller says drugmaker at risk of a government crackdown.

Midday Report: Pharma Stocks Jump on Trump Win; Nasdaq Plummets

Midday Report: Pharma Stocks Jump on Trump Win; Nasdaq Plummets

Wall Street ran at two speeds with the Dow Jones Industrial Average setting a record high earlier in the day while the Nasdaq plummeted into the red.

Donald Trump Election Victory Boosts Some Stocks and Sectors

Donald Trump Election Victory Boosts Some Stocks and Sectors

As we all know, the stock market and the economy abhor uncertainty.

What to Watch Wednesday: Election Aftermath, Mylan Earnings

What to Watch Wednesday: Election Aftermath, Mylan Earnings

On Wednesday, November 9, investors will grapple with the aftermath of Tuesday's presidential election, while parsing various earnings reports.

What Jim Cramer Expects From Mylan's Quarterly Results on Wednesday

What Jim Cramer Expects From Mylan's Quarterly Results on Wednesday

Jim Cramer is keeping an eye on quarterly results from Mylan which are due to be released on Wednesday after the markets close.

My Takeaways and Observations

"Dougie, take what Mr. Market gives you." -- Grandma Koufax And I did, Grandma Koufax.   A consecutive nine-day market drop was snapped as we regained most that was lost in that period.   Today was a great day. (Boy, would I like to annualize the pe...

What to Watch This Week: Presidential Election, Mylan Earnings

What to Watch This Week: Presidential Election, Mylan Earnings

For the week of November 7, all eyes will be on Tuesday's presidential election.

Biopharma: It's Darkest Before the Dawn

Biopharma: It's Darkest Before the Dawn

Thursday felt a lot like capitulation in this space. I was buying.

My Takeaways and Observations (Early Edition)

I have been warning about weakening breadth and narrow leadership for weeks and months.   What have we gotten? Eight straight days (in a row) down for the first time since 2008.   But, with stocks suffering from election uncertainties and given the ...

Valeant Skyrockets on Rumored $10B Salix Sale

Valeant Skyrockets on Rumored $10B Salix Sale

Investors rush to buy the drugmaker's stock following chatter of a much-needed megadeal.

McKesson Shares Plunge on Drug Price Cuts

McKesson Shares Plunge on Drug Price Cuts

Shares of the drug distributor were falling sharply Friday.

Stressed Out: Valeant Shareholders Flee on McKesson Warning

Stressed Out: Valeant Shareholders Flee on McKesson Warning

The drugmaker's shares were hammered Friday on news that the industry is slashing prices.